A Streamlined, End-To-End Solution For Robust And Efficient Large-Scale CAR T Manufacturing

As CAR T cell therapies expand beyond refractory indications into earlier treatment settings, manufacturing infrastructure faces mounting pressure to scale without introducing quality or safety trade-offs. Conventional open and manual workflows struggle to meet these demands, creating bottlenecks that can slow patient access. Automated, closed-system platforms offer a path forward, and recent work referenced in Sidana et al. (2026) has demonstrated that compressing activation, transduction, and expansion from several weeks to just days is achievable without compromising functional potency, proliferative capacity, or antigen-specific activity. This application note details an end-to-end approach to large-scale CAR T production designed around those accelerated processing steps.

Explore the methodology and performance data to see how the workflow holds up at scale.